Berheto Tezera Moshago, Haile Demissew Berihun, Mohammed Salahuddin
Department of Public Health, Aman College of Health Sciences, Mizan-Teferi, Ethiopia.
Department of Pharmacy, College of Health Sciences, Mizan-Tepi University, Mizan-Teferi, Ethiopia.
N Am J Med Sci. 2014 Sep;6(9):453-9. doi: 10.4103/1947-2714.141636.
Long-term regular follow up of ART is an important component of HIV care. Patients who are lost to follow-up (LTFU) while on treatment compromise their own health and the long-term success of ART programs.
This study was aimed at determining the incidence and risk factors for LTFU in HIV patients on ART at ART clinic of Mizan-Aman General Hospital, Ethiopia.
A retrospective cohort study of 2133 people living with HIV/AIDS and attending an ART clinic between 2005 and 2013 was undertaken. LTFU was defined as not taking an ART refill for a period of 3 months or longer from the last attendance for refill and not yet classified as 'dead' or 'transferred-out'. The log-rank test was used to measure differences in time to LTFU between groups and Cox proportional hazards modeling was used to measure predictors of LTFU.
Of 2133 patients, 53.9% were female. The mean (SD) age of the cohort was 31.5 (8.0), 16 (2.2), and 3.8 (3.0) years for adults, adolescents, and children, respectively. Around 574 (26.7%) patients were defined as LTFU. The cumulative incidence of LTFU was 8.8 (95% CIs 8.1-9.6) per 1000 person months. Patients with regimen substitution (HR 5.2; 95% CIs 3.6-7.3), non-isoniazid (INH) prophylaxis (HR 3.7; 95% CIs 2.3-6.2), adolescent (HR 2.1; 95% CIs 1.3-3.4), and had a baseline CD4 count < 200 cells/mm(3) (HR 1.7, 95% CIs 1.3-2.2) were at higher risk of LTFU. WHO clinical stage III (HR 0.6; 95% CIs 0.4-0.9) and IV (HR 0.8; 95% CIs 0.6-1.0) patients at entry were less likely to be LTFU than clinical stage I patients. There was no significant difference in risk of LTFU in males and females.
Overall, these data suggested that LTFU in this study was high. Patients phase of life, drug related factors, and clinical stages were associated with LTFU in this study. Effective control measures in the at-risk population need to be implemented to improve retention.
抗逆转录病毒治疗(ART)的长期定期随访是艾滋病护理的重要组成部分。接受治疗时失访(LTFU)的患者会损害自身健康以及ART项目的长期成效。
本研究旨在确定埃塞俄米亚米赞-阿曼综合医院ART诊所接受ART治疗的HIV患者中LTFU的发生率及危险因素。
对2005年至2013年间在一家ART诊所就诊的2133例HIV/AIDS患者进行了一项回顾性队列研究。LTFU定义为自上次取药就诊后连续3个月或更长时间未取ART药物续方,且尚未被归类为“死亡”或“转出”。采用对数秩检验来衡量各组间至LTFU时间的差异,并使用Cox比例风险模型来衡量LTFU的预测因素。
2133例患者中,53.9%为女性。该队列的平均(标准差)年龄,成年人、青少年和儿童分别为31.5(8.0)岁、16(2.2)岁和3.8(3.0)岁。约574例(26.7%)患者被定义为LTFU。LTFU的累积发生率为每1000人月8.8(95%可信区间8.1 - 9.6)。接受方案替换的患者(风险比[HR] 5.2;95%可信区间3.6 - 7.3)、未接受异烟肼(INH)预防性治疗的患者(HR 3.7;95%可信区间2.3 - 6.2)、青少年患者(HR 2.1;95%可信区间1.3 - 3.4)以及基线CD4细胞计数<200个/mm³的患者(HR 1.7,95%可信区间1.3 - 2.2)发生LTFU的风险更高。入组时处于世界卫生组织临床分期III期(HR 0.6;95%可信区间0.4 - 0.9)和IV期(HR 0.8;95%可信区间0.6 - 1.0)的患者比临床I期患者发生LTFU的可能性更小。男性和女性发生LTFU的风险无显著差异。
总体而言,这些数据表明本研究中的LTFU发生率较高。本研究中,患者的生活阶段、药物相关因素和临床分期与LTFU有关。需要对高危人群实施有效的控制措施以提高留存率。